Delving into the Latest Updates on IOT-022 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

farnesoid X receptor agonists (Inorbit Therapeutics)

Target

FXR

Mechanism

FXR agonists(Bile acid receptor FXR agonists)

Therapeutic Areas

Digestive System Disorders

Active Indication

Nonalcoholic Steatohepatitis

Inactive Indication-

Originator Organization

Inorbit Therapeutics ABStartup

Active Organization

Inorbit Therapeutics ABStartup

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Cholestatic liver disease is a group of diseases in which bile acid accumulates in the liver for various reasons, resulting in abnormal liver biochemical indicators and histological damage. Cholestasis can be divided into intrahepatic cholestasis and extrahepatic cholestasis, which will contribute to liver damage and progress to liver fibrosis and cirrhosis. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis are the two most typical cholestatic liver diseases. Ursodeoxycholic acid is currently the first-line treatment for PBC, while obeticholic acid, budesonide and fibrates have also shown good potential in the treatment of PBC. There are currently no official drugs approved to treat primary sclerosing cholangitis, and the use of ursodeoxycholic acid may have certain clinical benefits. At present, progress has been made in new treatment directions for cholestatic liver disease, including fibroblast growth factor 19, cholestyramine, S-adenosyl-L-methionine, steroid drugs, farnesoid X receptor agonists, and more. Considerable progress has been made in the management of cholestatic liver disease but there are still many opportunities and challenges. In this review, we summarized the recommended guidelines for the management of cholestatic disease and the progress of new drug research and development, in order to provide an important reference for the clinical practice of cholestatic liver disease.

01 Jan 2006·Folia Pharmacologica Japonica

治療薬シリーズ（８）緑内障　　１）緑内障治療薬の基礎

Review

Author: Shimazaki, Atsushi

100 Deals associated with IOT-022

Login to view more data